IDE196 + Crizotinib + Pembrolizumab + Ipilimumab + Nivolumab + Dacarbazine
Phase 2/3Active 0 watching 0 views this week📈 Rising
60
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Metastatic Uveal Melanoma
Conditions
Metastatic Uveal Melanoma
Trial Timeline
Oct 31, 2023 → Jan 15, 2028
NCT ID
NCT05987332About IDE196 + Crizotinib + Pembrolizumab + Ipilimumab + Nivolumab + Dacarbazine
IDE196 + Crizotinib + Pembrolizumab + Ipilimumab + Nivolumab + Dacarbazine is a phase 2/3 stage product being developed by IDEAYA Biosciences for Metastatic Uveal Melanoma. The current trial status is active. This product is registered under clinical trial identifier NCT05987332. Target conditions include Metastatic Uveal Melanoma.
Hype Score Breakdown
Clinical
22
Activity
15
Company
5
Novelty
7
Community
8
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05987332 | Phase 2/3 | Active |
Competing Products
20 competing products in Metastatic Uveal Melanoma